Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CT303
- Development stage
- Unknown
- Lead developer
- GC Cell
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
CT303 is an allogeneic cell therapy product consisting of mesenchymal stem cells (MSCs) derived from human tonsil tissue. Developed by GC Cell Corporation, CT303 is designed to treat inflammatory and autoimmune conditions by leveraging the immunomodulatory and anti-inflammatory properties of MSCs. Tonsil-derived MSCs are reported to have superior proliferation rates and potent immunosuppressive capabilities compared to MSCs derived from bone marrow or adipose tissue. The therapy is currently being evaluated in Phase 1 clinical trials for the treatment of moderate to severe plaque psoriasis and acute respiratory distress syndrome (ARDS). By secreting various cytokines and growth factors, CT303 aims to suppress overactive immune responses and promote tissue repair and regeneration.
- Other names
- Tonsil-derived mesenchymal stem cellsT-MSCallogeneic tonsil-derived mesenchymal stem cells
Beyond the preview
Go deeper on CT303.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CT303.